Navigation Links
Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis

BOCA RATON, Fla.--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publication in the Critical Reviews in Immunology special conference issue.

The article, entitled "Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application," discusses the background and reasoning behind ReceptoPharm's research on its treatment for Multiple Sclerosis (MS). The Company has completed Phase I studies and is preparing to begin its Phase II human clinical trials.

"We are honored to have our paper accepted for publication in such a well respected journal," commented Paul Reid, CEO of ReceptoPharm, Inc. "Alpha-Cobratoxin could play an important role in treating Multiple Sclerosis and we believe it is important to disseminate our research throughout the scientific community," he added.

Recently, ReceptoPharm announced it received a letter of intent to create a joint venture in China aimed at developing the Company's antiviral drug, RPI-MN, for the Chinese market. RPI-MN is ReceptoPharm's lead drug candidate being researched for the treatment of HIV/AIDS and other viral disorders.

About Critical Reviews in Immunology

The great advances in immunology in recent years make this field one of the most rapidly growing in biological sciences. Critical Reviews(TM) in Immunology presents a balanced overview of contemporary immunology and melds together molecular immunology and immunobiology. The Journal is published six times each year.

http://www.begellhouse.com/journals/2ff21abf44b19838.html

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, l icensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of the ReceptoPharm article should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact

Nutra Pharma Corp.
Investor Relations:
David Isserman, 877-895-5647
IR@nutrapharma.com


'"/>




Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Natalie Jill is a well respected ... preparation of the launch of her new book: Natalie Jill’s 7 Day Jump Start: ... designed to jump start a new healthy lifestyle featuring simple recipes using MitoXcell’s raw ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco ... compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . ... retail starting at $59.95) uses 2 included CR-123 batteries to produce up to ...
(Date:5/4/2016)... Prairie du Sac, Wisconsin (PRWEB) , ... ... ... The OMNIFORCE collection delivers next-level compression and support for knees, ankles, and ... a great value. , Innovative 3D flat-bed manufacturing (opposed to ineffective circular ...
(Date:5/4/2016)... ... May 04, 2016 , ... Mediware Information Systems, Inc ... application that helps blood and marrow transplant (BMT) programs meet compliance and accreditation ... has continued to enhance core application features. These enhancements are designed to help ...
(Date:5/4/2016)... ... May 04, 2016 , ... Over 40 athletic trainer’s (ATs) and athletic training ... the annual “Hike to Harrisburg” advocacy day. The annual lobbying effort is a ... Group. The goal for the day was to educate the elected legislators and ...
Breaking Medicine News(10 mins):